Dr. Burns C. Blaxall is Principal Consultant at PMG Insights, advising healthcare organizations, as well as national and international health systems, on optimizing the adoption of proactive precision medicine and value-based care.

He previously served as Senior Vice President of Precision Medicine at Aranscia, where he drove large-scale implementation of precision medicine strategies across health systems, payers, PBMs, employers, and provider networks.

Prior to that, he was the founding Executive Director of Precision Health at The Christ Hospital Health Network, where he built a nationally recognized program integrating hereditary risk screening, population health, and a pioneering pharmacogenomics (PGx) initiative. Under his leadership, the program launched one of the first prospective, randomized controlled trials of comprehensive PGx testing and achieved patient satisfaction scores in the 99th percentile.

Earlier in his career, Dr. Blaxall established and directed translational and clinical research centers, serving as principal investigator on numerous NIH and foundation grants. He has chaired NIH and foundation peer review panels and held editorial leadership positions for several scientific journals.

Dr. Blaxall earned his PhD in Pharmacology from the University of Colorado and has held academic and leadership appointments at Duke University, the University of Rochester, Cincinnati Children’s Hospital, and the University of Cincinnati, where he continues to serve as Adjunct Professor.

An elected fellow of multiple professional societies, Dr. Blaxall holds several patents, has delivered more than 200 invited lectures across six continents, and published nearly 100 peer-reviewed manuscripts.

He has received numerous honors and awards and continues to serve in leadership roles within professional societies and boards dedicated to precision medicine, pharmacogenomics, and therapeutic discovery.